• No conditions by Spanish antitrust authority
• Closing of transaction expected by January 31, 2017

Fresenius Helios today received antitrust approval to acquire Quirónsalud, Spain’s largest private hospital operator. The relevant Spanish antitrust authority has approved the transaction without imposing conditions. The acquisition can therefore be closed by January 31, 2017. Quirónsalud will be consolidated as of February 1, 2017.

Quirónsalud’s network is comprised of 43 hospitals, 39 outpatient centers and around 300 Occupational Risk Prevention (“ORP”) centers located in all economically important areas in Spain. The company has about 35,000 employees and offers the full spectrum of inpatient and outpatient care. With the acquisition, Fresenius Helios strengthens its position as Europe’s largest private hospital operator.

Given the expected meaningful accretion to Group sales and earnings, Fresenius will publish new mid-term targets as part of its full-year 2016 reporting.

 

 

 

Fresenius successfully placed €1.0 billion of Schuldschein Loans. Given the substantial investor demand, the volume of the issuance was significantly upsized. The Schuldschein Loans were issued in tranches of five, seven and ten years with fixed and variable interest rates. The proceeds will be used general corporate purposes and the acquisition of Quirónsalud. Funding of the transaction will be on January 31, 2017. More than 230 investors participated. The placement was arranged by Bayerische Landesbank, Deutsche Bank AG, DZ BANK and NORD/LB Norddeutsche Landesbank Girozentrale.

Fresenius successfully placed €1.0 billion of Schuldschein Loans. Given the substantial investor demand, the volume of the issuance was significantly upsized. The Schuldschein Loans were issued in tranches of five, seven and ten years with fixed and variable interest rates. The proceeds will be used general corporate purposes and the acquisition of Quirónsalud. Funding of the transaction will be on January 31, 2017. More than 230 investors participated. The placement was arranged by Bayerische Landesbank, Deutsche Bank AG, DZ BANK and NORD/LB Norddeutsche Landesbank Girozentrale.

Heparin Sodium, an anticoagulent, is now available in the company’s Simplist™ ready-to-administer prefilled syringe in the United States. This marks the second new product launch for the Simplist™ line following ownership by Fresenius Kabi. The launch expands Fresenius Kabi’s overall Heparin portfolio.

CATSmart is Fresenius Kabi’s next-generation continuous autotransfusion system, which helps reduce blood loss during surgery. CATSmart will be distributed in the U.S. by Terumo Cardiovascular Group. Fresenius Kabi USA and Terumo Cardiovascular Group have signed an exclusive, five-year distribution agreement for CATSmart.